Urocortin 3: Haemodynamic, hormonal, and renal effects in experimental heart failure

European Heart Journal

Volumn 27, Issue 17, 2006, Pages 2088-2098

  Rademaker, Miriam T ^a   Cameron, Vicky A ^a   Charles, Chris J ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Haemodynamics; Heart failure; Hormones; Sodium; Urocortin 3

Indexed keywords

ADRENALIN; ALDOSTERONE; ENDOTHELIN 1; RENIN; UROCORTIN III; VASOPRESSIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HEART OUTPUT; HEMODYNAMICS; HORMONE ACTION; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; SHEEP; SODIUM EXCRETION; URINE VOLUME; VASCULAR RESISTANCE; VASOPRESSIN BLOOD LEVEL;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; ELECTROLYTES; FEMALE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HEART RATE; HEMATOCRIT; HORMONES; SHEEP; UROCORTINS; VASCULAR RESISTANCE;

EID: 33748777684     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl138     Document Type: Article

References (34)

1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-292.
2. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Nat Acad Sci USA 2001;98:2843-2848.
3. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Nat Acad Sci USA 2001;98:7570-7575.
4. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002;87:340-346.
5. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001;7:605-611.
6. Fukuda T, Takahashi K, Suzuki T, Saruta M, Watanabe M, Nakata T, Sasano H. Urocortin 1, urocortin 3/stresscopin, and corticotropin-releasing factor receptors in human adrenal and its disorders. J Clin Endocrinol Metab 2005;90:4671-4678.
7. Takahashi K, Totsune K, Murakami O, Saruta M, Nakabayashi M, Suzuki T, Sasano H, Shibahara S. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 2004;89:1897-1903.
8. Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS. Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 2003;35:1295-1305.
9. Baigent SM, Lowry PJ. mRNA expression profiles for corticotrophin- releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J Mol Endocrinol 2000;25:43-52.
10. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 2004;143:508-514.
11. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Nat Acad Sci USA 2004;101:3697-3702.
12. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997;272:H2115-H2122.
13. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ, Finn DA, Low MJ, Rittenberg MB, Stenzel P, Stenzel-Poore MP. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genetics 2000;24:403-409.
14. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 2002;40:1495-1505.
15. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 2005;112:3624-3632.
16. Kageyama K, Furukawa K, Miki I, Terui K, Motomura S, Suda T. Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc Pharmacol 2003;42:561-565.
17. Chu CP, Qiu DL, Kato K, Kunitake T, Watanabe S, Yu NS, Nakazato M, Kannan H. Central stresscopin modulates cardiovascular function through the adrenal medulla in conscious rats. Regul Peptides 2004;119:53-59.
18. Perrin MH, DiGruccio MR, Koerber SC, Rivier JE, Kunitake KS, Bain DL, Fischer WH, Vale WW. A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity. J Biol Chem 2003;278:15595-15600.
19. Pelleymounter MA, Joppa M, Ling N, Foster AC. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 2004;25:659-666.
20. Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS. Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun 2005;328:442-448.
21. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during the onset and offset of ovine heart failure: role of ANP. Am J Physiol 1989;256:H1052-H1059.
22. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 2001;169:177-183.
23. Abdelrahman AM, Lin Lim S, Pang CC. Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats. Eur J Pharmacol 2005;510:107-111.
24. Saruta M, Takahashi K, Suzuki T, Fukuda T, Torii A, Sasano H. Urocortin 3/stresscopin in human colon: possible modulators of gastrointestinal function during stressful conditions. Peptides 2005;26:1196-1206.
25. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Plasma urocortin 1 in sheep: Regional sampling and effects of experimental heart failure. Peptides 2006;27:1801-1805.
26. Shi M, Yan X, Ryan DH, Harris RB. Identification of urocortin mRNA anti-sense transcripts in rat tissue. Brain Res Bull 2000;53:317-324.
27. Harada S, Imaki T, Naruse M, Chikada N, Nakajima K, Demura H. Urocortin mRNA is expressed in the enteric nervous system of the rat. Neurosci Lett 1999;267:125-128.
28. Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K, Takahashi M, Hirata K, Kawashima S, Yokozaki H, Yokoyama M. Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res 2006;43:131-138.
29. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol 2000;279:H3031-H3039.
30. Yao X, He GW, Chan FL, Lau CW, Tsang SY, Chen ZY, Huang Y. Endothelium-dependent and independent coronary relaxation induced by urocortin. J Card Surg 2002;17:347-349.
31. Weninger SC, Dunn AJ, Muglia LJ, Dikkes P, Miczek KA, Swiergiel AH, Berridge CW, Majzoub JA. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Nat Acad Sci USA 1999;96:8283-8288.
32. Robertson GL. Physiology of vasopressin, oxytocin, and thirst. In: Kenneth Becker, ed., Principles and Practice of Endocrinology and Metabolism. 3rd ed. Lippincott Williams & Wilkins Pub.; 2001, Chapter 25, p276-285.
33. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Endogenous urocortins reduce vascular tone and renin-aldosterone/ endothelin activity in experimental heart failure. Eur Heart J 2005;26:2046-2054.
34. Suda T, Kageyama K, Sakihara S, Nigawara T. Physiological roles of urocortins, human homologues of fish urotensin 1, and their receptors. Peptides 2004;25:1689-1701.